LONDON -(Dow Jones)- The U.K.'s health-care costs regulator said Wednesday it isn't recommending Bristol-Myers Squibb Co.'s (BMY) drug Orencia, also known as abatacept, for use in the state-funded National Health Service for treating adults with moderate to severe active rheumatoid arthritis who haven't responded to conventional non-biological anti-rheumatic drugs, largely due to cost considerations.
Explaining its draft decision, the National Institute for Health and Clinical Excellence, or NICE, said it already recommends a number of disease-modifying anti-rheumatic drugs, or Dmards, for second-line use for patients with moderate to severe active rheumatoid arthritis. These include adalimumab, etanercept, infliximab and certolizumab pegol.
Wednesday, March 30, 2011
UK's NICE Doesn't Back Use Of Bristol-Myers Squibb's Orencia - FoxBusiness.com
via foxbusiness.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment